Navigation Links
A prescription cream for unwanted facial hair,,

VaniqaT is a prescription drug which was approved by the FDA in the United States on July 31, 2000 for treating excessive facial hair in women, which is often part of hirsutism.

It may be a welcome alternative for women for whom this problem is considered serious enough to warrant tweezing, waxing, or shaving at least once a week for hair removal. Vaniqa is actually not a brand new drug, but rather a new topical-use version of the older drug eflornithine (brand name Ornidyl).

Vaniqa, like Viagra, is considered to be a "lifestyle drug", a drug which generally improves our quality of life, but is not considered to be essential for good health. Vaniqa is the first prescription drug approved in the United States to treat this condition. It was effective, compared to placebo, in approximately 25% of women who used it during the pre-release clinical trials. Although Vaniqa currently appears have few side effects, when used as directed, post-release experience often modifies the safety profile for new drugs.
'"/>




Page: 1

Related medicine news :

1. Patients Pressure Would Result In Overprescription
2. TV drug commercials prompt prescriptions
3. Status of some prescription drugs
4. Abuse of prescription drugs among youths on the rise
5. Bush’s new prescription drug plan, a complex puzzle for the citizen
6. Many Nonprescription Cough Medicines Proves Ineffective
7. A urine test for ease in prescription of drugs and therapies
8. Doctors to give complete information on prescriptions to patients
9. U S Government Allows Non-prescription Diet Pill
10. Lifestyle changes not prescription drugs to fight diabetes, say scientists
11. Sun burns treated with creams
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: prescription cream for unwanted facial hair

(Date:7/11/2014)... Microbiology testing is a highly dynamic ... which is expected to pose the biggest challenge to ... its growth to the ongoing spread of AIDS – ... a major factor leading to the upsurge of opportunistic ... a broader availability of immunosuppressants, among others. , ...
(Date:7/11/2014)... 11, 2014 As part of ... Liebhard LLP has been closely monitoring the ongoing ... (FDA) Obstetrics and Gynecology Devices Panel, which ... the cancer risks associated with the use of ... to a report published by Dow Jones Business ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers ... Geography - 2018,” defines and segments the specialty ... analysis and forecast of the volumes and values ... aramids, meta aramids, UHMW Polyethylene, carbon fiber, partially ... PBI fiber, PBO fiber, and liquid crystal polymer ...
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Datalogic brings a new ... sanitation hospital wide. With their new Gryphon GD4400 ... disease, like the devastating MRSA, which claimed 5,500 lives, ... GD4400-HC 2D and the Gryphon GM4400-HC 2D readers ... can even read barcodes off of troublesome LCD monitors, ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... Health and Safety Products Company, Kidz-Med, Inc. takes special notice ... Kidz-Med, Inc. along with its parent company, American Scientific Resources, ... role models for all families. , , In 1994, ... Sunday of each July, as a national day of commemoration, ...
... exposure during pregnancy to miniscule levels of carbon monoxide damages ... The journal BMC (BioMed Central) Neuroscience published ... "We expected the placenta to protect fetuses from the ... Edmond, professor emeritus of biological chemistry at the David Geffen ...
... Evanston, Ill., June 25 Lenox Hill Heart and ... Inc. (Mentice) partnered to coordinate the 1st trans-septal specific ... the Mentice VIST(TM) endovascular simulator to enhance the training ... , , The two-day course included didactic presentations, ...
... Reduce Access to Care for Dying Americans , , ... the country sent a letter to President Barack Obama urging him ... 1, 2009. , , The cuts threaten to ... patients and their family caregivers receive from hospice providers each year. ...
... , Funding supports multiple commercial, emerging and pilot projects ... for Stem Cell & Regenerative Medicine (CSCRM), comprised of ... (CC), University Hospitals (UH), and Athersys, Inc. has received ... Research Commercialization Program. The funding will help support new ...
... to Millennium Research Group (MRG), the global authority ... procedure adoption will accelerate over the next five ... deep vein thrombosis (DVT). Although the ATTRACT (Acute ... trial, which will compare catheter-directed thrombolysis (CDT) to ...
Cached Medicine News:Health News:Parents' Day is Coming - Kidz-Med Celebrates the Role of Parents 2Health News:Tiny levels of carbon monoxide damage fetal brain 2Health News:Lenox Hill Heart and Vascular Institute of New York and Mentice, Inc. Announce the Successful Completion of Their 1st Trans-septal Cardiac Catheterization Training Course: A Comprehensive Hands-On Tutorial with Certification on June 12th and 13th 2009 in 2Health News:Lenox Hill Heart and Vascular Institute of New York and Mentice, Inc. Announce the Successful Completion of Their 1st Trans-septal Cardiac Catheterization Training Course: A Comprehensive Hands-On Tutorial with Certification on June 12th and 13th 2009 in 3Health News:Hospice Community Urges President Obama to Stop Funding Cuts 2Health News:Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine 2Health News:Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine 3Health News:Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine 4Health News:Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine 5Health News:Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group 2Health News:Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group 3
(Date:7/11/2014)... Research and Markets has announced the addition ... Industry Report 2014" report to their offering. ... And Chinese Medical X-Ray Film Industry Report 2014 is ... of the Global medical X-ray film industry with a ... a basic overview of the industry including definitions, classifications, ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Dr. Roy Fleischmann from ... presenting data from Lexicon,s LX2931 Phase 2 ... American College of Rheumatology on Wednesday, November 9, 2011 ...
... Nov. 8, 2011 Mesa Laboratories, Inc. (NASDAQ: ... declared a regular quarterly dividend of $.13 per share of ... dividend will be payable December 15, 2011, to shareholders of ... in 1984 Mesa Labs has maintained strong cash positions and ...
Cached Medicine Technology:LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference 2LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference 3
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Maximum contact. Minimum wear. Outstanding results....
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
...
Medicine Products: